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The early phase of systemic sclerosis (SSc) presents edema as one of the main features:
this is clinically evident in the digital swelling (puffy fingers) as well as in the edematous
skin infiltration of the early active diffuse subset. Other organs could be affected by
this same disease process, such as the lung (with the appearance of ground glass
opacities) and the heart (with edematous changes on cardiac magnetic resonance
imaging). The genesis of tissue edema is tightly linked to pathological changes in the
endothelium: various reports demonstrated the effect of transforming growth factor β,
vascular endothelial growth factor and hypoxia-reperfusion damage with reactive oxygen
species generation in altering vascular permeability and extravasation, in particular
in SSc. This condition has an alteration in the glycocalyx thickness, reducing the
protection of the vessel wall and causing non-fibrotic interstitial edema, a marker of
vascular leak. Moreover, changes in the junctional adhesion molecule family and other
adhesion molecules, such as ICAM and VCAM, are associated with an increasedmyeloid
cells’ extravasation in the skin and increased myofibroblasts transformation with further
vascular leak and cellular migration. This mini-review examines current knowledge on
determinants of vascular leak in SSc, shedding light on the role of vascular protection.
This could enhance further studies in the light of drug development for early treatment,
suggesting that the control of vascular leakage should be considered in the same way
that vasodilation and inflammation reduction, as potential therapeutic targets.
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Systemic sclerosis (SSc) is characterized, in its early phase, by
the prominent interplay between the microvasculature and the
immune system (1). The injury to the endothelium and the vessel
wall, the activation and perivascular homing of inflammatory
cells and the contemporary loss of the vascular tone control are
a major triad contributing to the initiation and maintenance
of vascular leak (2). The aim of this review is to examine the
characteristics and mechanisms of vascular leaking in SSc.
ANATOMY
The vessel structure depends on its size and function:
while larger arteries, arterioles, veins and venules have an
endothelial layer plus varying amounts of surrounding muscular
cells, capillaries and post-capillary venules have an inner
surface coat overlying the endothelium called the glycocalyx,
a negatively charged glycosaminoglycan (GAG) layer, and
are usually surrounded by pericytes (3). The endothelium
represents a barrier to extravasation, preventing circulating
cells and macromolecules from crossing the lipid membrane.
Endothelial cells (ECs) are anchored via integrins to a basement
membrane (BM) which can be fenestrated or continuous. Central
nervous system, connective tissue, heart and muscle have a
continuous endothelium: ECs are linked together with tight
intercellular junctions, adherent junction (VE-cadherin and
catenin) and tight protein and glycoprotein junctions (occludins,
claudins, and junctional adhesion molecules -JAMs- family
members) controlling cell trafficking and protein and fluids
passage (4).
In specific conditions, an intercellular vascular leak can be a
physiological reparative event, such as during neovascularization
following wound healing. This is consecutively characterized
by BM degradation, pericyte detachment, endothelial thinning




Independent of BM structure, various angiogenic and
lymphangiogenic mediators derived by several inflammatory
effector cells (such as mast cells, eosinophils, basophils,
macrophages, etc.) can regulate physiological vascular
permeability and extravasation, such as the vascular endothelial
growth factor (VEGF) (6). VEGF isoforms signal through
different members of the VEGF receptors family, which
are expressed on several cells including ECs. VEGF is a
mitogen and a vasodilator stimulating vascular permeability
(7, 8), affecting perivascular pericytes and concomitantly
increasing cellular migration (9). Moreover, VEGF-A induces
VE-cadherin phosphorylation thus impairing endothelial
barrier integrity and increasing vascular permeability (10).
Angiopoietin (Ang) system represents a complementary
pathway in the regulation of vascular endothelial barrier
function (11). In humans, Ang1 and Ang2 are, respectively, a
full agonist and a partial agonist of the Tie2 receptor on ECs:
the former inhibits endothelial permeability, the latter induces it
(12, 13).
In addition, transforming growth factor beta (TGFβ), a potent
inhibitor of ECs proliferation and migration, induces pericyte
differentiation, production of BM and induces VEGF inhibiting
Ang1 expression in pericytes and fibroblasts. Therefore,
TGFβ can exacerbate vascular leak in certain pathological
conditions (14).
Capillary permeability may be significantly increased by
hypoxia-reperfusion injury. In a pig-heart model, in fact,
reperfusion caused damage to the glycocalyx, with increased
serum levels of heparan-sulfate derived from GAGs shedding,
influenced by oxygen-derived free radicals and xanthine-
oxidoreductase activity (15).
PATHOLOGICAL CAPILLARY LEAKING
Capillary leak may take place in several diseases due to local
pathological conditions and the following are prototypes arising
from different origins:
1) Anti-angiogenic and potential permeability inhibitors have
been demonstrated in neoplasms (16),
2) Hypoxia-induced VEGF production can determine vascular
leak and local edema in ischemic diseases such as stroke and
myocardial infarction (17),
3) Pathological or mechanical endothelial stretch induces
increased vascular permeability in pulmonary diseases
including asthma (18), acute and ventilator-induced lung
injury (19),
4) Hypoxia-inducedVEGF production has been demonstrated in
ocular conditions such as diabetic retinopathy or age-related
macular degeneration (20).
Similarly, systemic inflammatory pathologies such as sepsis,
pancreatitis and major traumas may induce a capillary leak.
These are characterized by an increase in pro-inflammatory
mediators (e.g., G-CSF, IL-6, IL-8, sTNFR1), followed by
an increase of endothelial protective proteins, like Ang1,
and of heparin binding proteins derived from glycocalyx
damage (21, 22).
A distinct pathological entity called Systemic Capillary
Leak Syndrome is characterized by arterial hypotension,
hemoconcentration and low albumin levels with hypotensive
shock and anasarca. In these patients, pro-inflammatory and
endothelial mediators are significantly increased (23) and prompt
treatment is required (24).
VASCULAR LEAKING IN SSc
In SSc, endothelial injury is a pivotal pathological event (25)
which may have twofold explanations. Firstly, several unknown
toxic stimuli (including ischemia-reperfusion) may induce a state
of persistent endothelial activation resulting in apoptosis and
detachment. Altered vasculature causes the direct activation of
the alternative complement and coagulation cascades, leading
to abnormal platelet activation (26), which amplifies and
Frontiers in Immunology | www.frontiersin.org 2 September 2018 | Volume 9 | Article 2045
Bruni et al. Vascular Leaking in Systemic Sclerosis
maintains vascular permeability and promotes the formation of
intravascular fibrin deposits contributing to intimal proliferation,
luminal narrowing and vessel obstruction (26). Secondly, there is
an ineffective ability to respond to all these insults by promoting
vascular repair (27).
In the pathogenetic progression, the vascular leak could be due
to the modification of endothelial glycocalyx, vesiculo-vacuolar
organelles, extracellular matrix (ECM), BM, intercellular
junctions, cytoskeletal proteins and/or vascular pericytes. Using
electron microscopy, SSc skin capillaries revealed intercellular
gaps, vacuolization and destruction of ECs, reduplication of
the basal lamina, perivascular cellular infiltrates and fibroblasts
and pericytes with an enlarged rough endoplasmic reticulum
accompanied by perivascular fibrosis (28–30).
In early SSc, vasculopathy is paralleled by an increased
production of pro-angiogenic factors (e.g., VEGF, endothelin-
1) (31, 32) and ECs defective response. These early events
lead to vascular tone dysfunction, reduced capillary blood
flow and chronic tissue hypoxia, further exacerbated by ECM
accumulation and fibrosis (32). Biomarkers of vascular leak
in SSc suggest intracellular signaling cascades impact on
endothelial cytoskeletal and junctional proteins. The localization
and function of junctional proteins and vesicular bodies
can be significantly influenced by vasoactive substances,
inflammatory mediators, and mechano-transduction. Damaged
cells and inflammatory cells produce signaling mediators,
such as histamine, TGFβ and VEGF, that can directly
increase vascular permeability (2, 8, 33, 34). While perivascular
cellular infiltrates and EC damage seemingly precede fibrosis
(28), once hyperpermeability or leak occurs, the ECM is
important for the propagation of fibrosis through its direct
influence on fibroblast-myofibroblast transition and endothelial-
to-mesenchymal transition (EndoMT) and the generation of
profibrotic myofibroblasts (35).
Taken together, these events lead to a microcirculatory
endothelial dysfunction, characterized by inflammatory immune
cells surrounding microvessels (36), and to an organ damage,
both independent from the rate of fibrosis (37). The role
of microvascular endothelium is pivotal in triggering the
activation of tissue cells, such as dendritic cells and macrophages,
through the presentation of self-antigens, and myofibroblasts,
through the release of TGFβ and other cytokines and growth
factors (26).
IMMUNE CELLS AND VASCULAR
LEAKING IN SSc
Genetic factors are implicated in SSc development and are related
to immunity and inflammation, thus suggesting a crucial role of
the autoimmune dysregulation in all the phases of the disease (1),
including vascular leak onset (26, 27, 36–43).
The response of the innate immune system against pathogens
or non-specific damage is achieved through the activation of the
so-called pattern recognition receptors, in particular the Toll-
like receptors (TLRs). TLRs are evolutionary conserved receptors
that, upon binding to their ligands, trigger the inflammatory
response and induce several cellular changes (44). In addition to
microbial antigens, TLRs can recognize endogenous molecules,
contributing to the pathogenesis of many autoimmune diseases,
including SSc (45, 46). The damage-associated molecular
patterns (DAMPs), released from endogenous cells upon necrosis
or tissue injury, generated by stressed cells, or resulting
from mechanical or biochemical fragmentation of extracellular
molecules, serve as an alarm “signal” for cells via TLRs (47).
The mechanism regulating DAMPs release and interaction
with the microenvironment is still poorly understood. The EC
stress and injury trigger the inflammatory response mainly
through the activation of NF-kB. Aberrant TLR signaling may be
involved at the onset and during progression of SSc, contributing
significantly to tissue inflammation and aberrant wound healing
process (47).
Evidence suggests that the perivascular infiltrate participates
in vessel wall remodeling (29). In early SSc, precursor cells
such as monocytes, recruited from the bone marrow, migrate
in the tissues (47) with T-cells and macrophages, to form the
perivascular infiltrate between collagen fibers (Figures 1A,a1,C).
Macrophages can generate different form of cells roughly
categorized as classically activated (M1) and alternatively
activated (M2) macrophages (48): M1 macrophages are effector
phagocytes with an enhanced microbicidal or tumoricidal
capacity, whereas M2-polarized macrophages are activated
mostly by IL-4, IL-13, and IL-10, as well as by CCL2 and IL-6 (49).
Commonly found during the peak of the profibrotic immune
response, M2 macrophages have been proposed as inducers of
wound healing, tissue fibrosis and remodeling in SSc. First, M2
macrophages suppress M1 responses and then promote collagen
synthesis and profibrotic cytokine release, and Th2 effector
responses. Consequently, if inflammation and tissue damage fail
to resolve, a persistent fibrotic state may arise (50).
In the early edematous phase of SSc, the perivascular infiltrate
is dominated by T-cells, with CD4+ T-cells predominating
over CD8+ T-cells. The T-cell infiltrate is characterized by
γδT-cells, mostly expressing the V1 chain (Vδ1+cells), which
are a “non-conventional” T-cell population able to recognize
non-peptidic antigens independent of major histocompatibility
(MHC) molecule (51). These cells represent another potential
mechanism that can contribute to the initial immune damage of
SSc (52). The role of the γδT-cells is not completely understood.
On one hand a defective regulatory function of γδT-cells may
play a role in the breakdown of tolerance contributing to
the early stages of the disease (53). Vδ1+-cells represent the
majority of γδT-cells found in SSc skin lesions (54), peripheral
circulation and bronchoalveolar lavage fluid suggesting an
effector rather than regulatory function (55). In SSc, Vδ1+ γδT-
cells are recruited by chemokines secreted by local cells (i.e.,
fibroblasts), starting immune-mediated endothelial damage. This
is demonstrated by the presence of the activation marker CD49d
mediating γδT-cells adherence to the ECs through the binding of
the vascular cell adhesion molecule-1 (VCAM-1) (56). CD49d-
VCAM-1 interactions are implicated in endothelial injury and
cytotoxicity of activated γδT-cells (55).
In SSc vasculopathy evolution, the contact of leukocytes
with ECs and fibroblasts is of paramount importance (57, 58).
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FIGURE 1 | Perivascular edema and inflammatory cell infiltration are prominent in skin of early diffuse cutaneous systemic sclerosis (SSc). Representative
microphotographs of paraffin-embedded skin sections from patients with early diffuse cutaneous SSc subjected to hematoxylin and eosin staining (A, a1, a2, B) or
double immunofluorescence staining for CD45/leukocyte common antigen (green) and CD31/pan-endothelial cell marker (red) with 4′,6-diamidino-2-phenylindole
(DAPI, blue) counterstain for nuclei (C) are shown. (a1) and (a2) represent higher magnifications of the boxed areas in (A). (a1) Infiltrating inflammatory cells are
observed around small dermal blood vessels (arrows). (a2) A dermal lymphatic vessel with an enlarged lumen (asterisk) is surrounded by edematous extracellular
matrix. (B) Edema is prominent around blood capillaries. The inset depicts a higher magnification view of the boxed area from the respective panel. (C) CD45-positive
inflammatory cells are widely found in the perivascular area. (D,E) Representative transmission electron microscopy microphotographs of ultrathin skin sections from
patients with early diffuse cutaneous SSc. (D) A blood capillary displays hypertrophic endothelial cells and is surrounded by edema and inflammatory cells. (E) A
lymphatic vessel surrounded by edema shows an enlarged lumen (asterisk). EC, endothelial cell; MC, mast cell; MO, mononuclear cell; P, pericyte; RBC, red blood cell.
The expression and function of several cell adhesion molecules
regulate the maintenance of trans-endothelial leukocyte
migration. In affected SSc skin, specific EC activation markers
are upregulated, including E-selectin, P-selectin, intercellular
adhesion molecule (ICAM), JAMs, platelet EC adhesion
molecule (PECAM), and vascular cell adhesion molecule
(VCAM), particularly on ECs and fibroblasts in proximity to
the perivascular infiltrate (55). Several other markers of EC
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activation, although expressed to a lesser extent, are also elevated
in the sera of SSc or certain SSc subtypes (i.e., von Willebrand
factor, fractalkine, β1/β2/β4 integrins, etc.) (58).
The complex role of the immune system in the pathogenesis
of SSc is further highlighted by the detection of substantial
differences in cytokine production in SSc, with differences
according to cutaneous and internal organ involvement (59, 60).
Recently, the role of the adaptive immune system in SSc
pathogenesis has been highlighted. In early SSc, Th1 and Th17
cells are predominant and pro-inflammatory cytokine release
drives inflammation, whereas Th2 cells predominate in the later
stages, participating through the release of profibrotic cytokines
(60).
Mast cells (MCs) and basophils have also been implicated
in the pathogenesis of systemic autoimmune diseases (SADs)
(61, 62). It is becoming evident that MCs and basophils can
be activated by a plethora of stimuli relevant in SADs (e.g.,
viral and bacterial products, complement, cytokines, etc.) and
can also modulate innate and adaptive immune responses (18).
MCs are implicated in different fibrotic conditions (renal fibrosis
and pulmonary fibrosis) (60) and have also been identified
in SSc dermis (47). Mast cells, due to their ability to inhibit
Treg cells and enhance generation of Th17 cells, are potential
antagonists of a proper development and function of Treg cells
(1). Interestingly, peripheral blood basophils are upregulated in
patients with SSc (63).
B-cells are yet another potential mediator of vascular
injury. In fact, highly specific autoantibodies (anti-topoisomerase
I, anticentromere and anti-RNA polymerase III antibodies)
appear years before the clinical disease (64). In SSc, the
immunoregulatory involvement of B-cells is demonstrated by the
finding that anti-EC antibodies induce apoptosis. In SSc sera,
a subset of autoantibodies against heterogeneous antigens on
ECs (referred to as AECA) are able to induce microvascular
EC apoptosis through antibody-dependent natural killer cell
cytotoxicity (47).
Finally, the involvement of the immune system seems to
be responsible not only for tissue inflammation but also as an
inducer of fibroblast-myofibroblast transition (65).
CUTANEOUS BLOOD CAPILLARY LEAK AS
PATHOGENIC INITIATOR OF LYMPHATIC
MICROANGIOPATHY IN SSc
Clinical and histological findings have shown that lesional SSc
skin exhibits lymphatic microcirculation abnormalities that may
be involved in the early edematous phase, when digital painless
swelling is a clinical hallmark (66–68). Of note, early blood
capillary leak may occur during the initiation of the cascade of
lymphatic microangiopathy (66). Indeed, dermal blood capillary
leaking causes greater amount of fluid and macromolecules in
the interstitium, with maximal increase in lymph flow provoking
micro-lymphatic insufficiency and consequent accumulation
of protein-rich interstitial fluid, clinically manifest as edema
(Figures 1A,a2,E) (66). The consequent inflammatory response
and fibrotic process then perpetuate micro-lymphatic injury in
a vicious circle similar to that occurring in chronic venous
insufficiency. The investigation of the cutaneous capillary
lymphatic system in SSc using fluorescence micro-lymphography
revealed an augmented dye expansion into the superficial
network of lymphatic capillaries and dermal backflow, postulated
to be the consequence of hampered drainage of interstitial
fluid into the deeper lymphatic collector vessels (66). Moreover,
disease duration correlated with the loss of the micro-lymphatic
network at the dorsum of the fingers (66). This evidence was
further corroborated by histological studies reporting that the
numbers of either lymphatic capillary or pre-collector vessels are
decreased in SSc skin, with the reduction of the latter being more
pronounced than that of capillaries (67, 68). In addition, such
a loss of cutaneous micro-lymphatics appears closely linked to
the progression of dermal fibrosis and development of fingertip
ulcers (67–69).
CLINICAL EVIDENCE AND
QUANTIFICATION OF VASCULAR LEAK IN
SSc
In SSc, capillaries not only undergo morphologic changes
that suggest vascular leak (29), but also display functional
deficits (70), resulting in a hyperpermeable state (Figures 1B–D).
Recovery of the normal vasculature requires resolution of
vascular leak (2). The inability of SSc microvessel to recover
from vascular leak increases the edema from lymphatic
microangiopathy (see above). In fact, the most typical SSc
clinical presentation is vascular dysfunction, as manifested by
Raynaud’s phenomenon, followed by the onset of edematous
puffy hands (71). As such, this early stage of hyperpermeability
prior to the onset of fibrosis would be an ideal target for
therapeutic intervention, thus highlighting the importance of
its characterization. While the skin is the primary organ that
has been studied in SSc, autopsy data suggests that all organs’
microvasculature is affected (72). Indeed, vascular leaking can
be also hypothesized in early lung involvement (with ground
glass opacities on high resolution computed tomography) as
well in the myocardial edema detected on cardiac magnetic
resonance (73).
Non-invasive investigational studies support a progressive
hyperpermeability of microvasculature in SSc. Nailfold
videocapillaroscopy (NVC) is one of the major components in
the 2013 classification of SSc (74), demonstrating progressive
loss of the peripheral vascular network, dilatation of capillaries,
deficient vascular repair and inadequate angiogenesis (75). While
NVC is efficient for measuring morphological microvascular
changes (microangiopathy), other methods, such as Laser
Doppler, thermography or Near Infrared Spectrometry (76),
are essential for the assessment of functional blood flow
abnormalities. Results published so far do not clearly define
the mechanistic changes of glycocalyx, ECM, BM, vesiculo-
vacuolar organelles, cellular junctions, cytoskeletal proteins,
and/or vascular pericytes abnormalities. Detailed longitudinal
studies are in progress to define a unified vascular phenotype
in SSc (77).
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FIGURE 2 | Schematic representation of the mechanisms leading to endothelial injury and capillary sufferance, evolving into vascular leaking.
Evaluation of sublingual microcirculation can detect both
morphological and functional capillary impairment and allows
measurement of the glycocalyx layer. A pilot study found
correlation of abnormal sublingual microcirculation, evaluated
by intravital microscopy using Sidestream Dark Field (SDF)
with a CapiScope HVCS handheld video capillary microscope
(KK Technology, Honiton, UK), suggesting a decrease in
glycocalyx thickness. Correlation between NVC capillary
density and sublingual capillary density measured by SDF
was discovered, supporting the concept of diffuse multi-organ
microcirculation abnormalities in SSc (78). In another study of
sublingual microcirculation, intravital microscopy demonstrated
that the perfused boundary region, a marker of the barrier
properties of endothelial glycocalyx, was higher in 40 SSc




Degradation of the endothelial barrier occurs in response to
perivascular inflammation and to reactive oxygen species (ROS)
generated by the ischemia-reperfusion injury, taking place in
SSc patients’ microvasculature (Figure 2). This phenomenon is
a noxious trigger to the endothelial barrier leading to opening of
the endothelial junctions, inflammatory cells homing, sustained
hyperpermeability and continuous vascular leak (Figure 2). In
early SSc, vascular and lymphatic angiopathy leads to leaking
into tissue and interstitial edema generation, clinically visible
as puffy fingers and detectable in NVC as a fluffy appearance
of giant capillaries. It is clear that this phenomenon is at its
zenith in the early edematous disease phase, is tightly linked
to significant perivascular homing of inflammatory cells and
progressively disappears with disease progression (32). From
the pathogenetic point of view, vascular leaking testifies to
the beginning of a process concentrated in the vessel wall
involving ECs, inflammatory cells as well as the other tissue
components. A pivotal role in these processes may be played
by endothelin-1, which was shown to drive vascular fragility
and endothelial dysfunction in animal models (80, 81), regulate
adhesion molecules expression (82) and cellular migration (83),
and to promote EndoMT (84). This was also indirectly proven by
the amelioration induced by endothelin-1 receptor antagonists,
manifested both clinically (85) and in NVC (86).
Therefore, the early SSc phase may be the ideal target to
achieve the paradigm “to close the door,” i.e., prevent leaking
into the tissues, mainly with a twofold strategy. The first to
induce disease remission with immune suppression by blocking
the vascular leaking, and in particular cellular trafficking, and
therefore the progression of the disease. The second, to achieve
vasoactive protection, restoring endothelial function and block
remodeling of the vessel wall. This combination regimen may
impact on disease evolution avoiding the progression to fibrosis.
The induction therapy dealing with early vascular leaking
needs to be carefully tested, including the possibility of using
early intense immunosuppression followed by a lower dose
“maintenance” treatment, assisted by vasoactive treatment and,
in case of already manifested fibrotic changes, anti-fibrotic
compounds (87).
In the future, increasing attention to vascular leaking is
warranted to better understand early SSc and to evaluate a new
strategic targeted therapy.
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